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In Brief
Recessive mutations in Parkin contribute
to Parkinson’s disease. Pickrell and
Huang et al. use a mouse model to
discover endogenous Parkin
preferentially protects dopaminergic
neurons from mitochondrial dysfunction.
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Parkinson’s disease (PD) is a neurodegenerative dis-
ease caused by the loss of dopaminergic neurons in
the substantia nigra. PARK2 mutations cause early-
onset forms of PD. PARK2 encodes an E3 ubiquitin
ligase, Parkin, that can selectively translocate to
dysfunctional mitochondria to promote their removal
by autophagy. However, Parkin knockout (KO) mice
do not display signs of neurodegeneration. To
assess Parkin function in vivo, we utilized a mouse
model that accumulates dysfunctional mitochondria
caused by an accelerated generation of mtDNA mu-
tations (Mutator mice). In the absence of Parkin,
dopaminergic neurons in Mutator mice degenerated
causing an L-DOPA reversible motor deficit. Other
neuronal populations were unaffected. Phosphory-
lated ubiquitin was increased in the brains of Mutator
mice, indicating PINK1-Parkin activation. Parkin
loss caused mitochondrial dysfunction and affected
the pathogenicity but not the levels of mtDNA
somatic mutations. A systemic loss of Parkin syner-
gizes with mitochondrial dysfunction causing dopa-
minergic neuron death modeling PD pathogenic
processes.
INTRODUCTION
Parkinson’sdisease (PD) is oneof themost commonprogressive,
age-related neurodegenerative diseases. Three neuropatholog-
ical signs characterize PD: the presence of a-synuclein-positive
neuronal inclusions known as Lewy bodies, the progressive
loss of dopaminergic neurons in the substantia nigra pars com-
pacta (SN) that project to the striatum, and the consequent stria-
tal dopamine (DA) depletion causing the disease’s classical
motor phenotypes (Dauer and Przedborski, 2003). The motor
symptoms (rigidity, bradykinesia, postural instability, and tremor)
appearwhen approximately 50%–60%of SNdopaminergic neu-rons degenerate (Fearnley and Lees, 1991). The majority of PD
cases are sporadic, and, to date, therapies remain limited.
There is a strong connection between the role of mitochondrial
defects and the pathogenesis of PD. Disruption of oxidative
phosphorylation (OXPHOS), particularly complex I, is believed
to be an important contributor to neuronal loss in PD (Schapira
et al., 1990a, 1990b). Dopaminergic neurons in both PD and
aged individuals display dysfunctional mitochondria accumu-
lating high levels of mitochondrial DNA (mtDNA) deletions
(Bender et al., 2006; Kraytsberg et al., 2006). Mitochondrial dis-
ease patients harboring POLG mutations (the polymerase
responsible for mtDNA replication) also accumulate mtDNA mu-
tations in dopaminergic neurons leading to nigrostriatal degener-
ation (Reeve et al., 2013).
PARK2 is the second most common gene mutated in cases of
early-onset familial PD (Kitada et al., 1998), and its mutations
have been associatedwithmitochondrial dysfunction. Recessive
mutations are responsible for loss of function of Parkin, disrupt-
ing its ubiquitin-ligase activity necessary to target dysfunctional
mitochondria for selective, autophagic destruction in a process
known as mitophagy (Pickrell and Youle, 2015). Although groups
have shown strong evidence that Parkin-mediated mitophagy
occurs in neurons (Ashrafi et al., 2014; Bingol et al., 2014), the
extensive studies of this pathway in cultured cells have failed to
reveal how Parkin contributes to PD pathogenesis and affects
dopaminergic neurons in vivo. Parkin-knockout (KO) mice do
not show significant motor phenotypes, DA metabolism abnor-
malities, or signs of nigrostriatal degeneration (Goldberg et al.,
2003; Kitada et al., 2009; Perez and Palmiter, 2005). There are
also no reportedPDmousemodelswhere dopaminergic neurons
degenerate without experimentally targeting these neurons spe-
cifically (Pickrell et al., 2013). Our data provide insight as to why
Parkin-KOmice haveno neurodegeneration and show the impor-
tance of endogenous Parkin in enforcing mitochondrial quality
control to protect dopaminergic neurons.
RESULTS
We hypothesized that the loss of endogenous Parkin may
be detrimental to neuronal health in a mouse model with mito-
chondrial dysfunction. To test this hypothesis, we used miceNeuron 87, 371–381, July 15, 2015 ª2015 Elsevier Inc. 371
homozygous for a proofreading deficiency in DNA polymerase g
(Mutator mice) as a model for mitochondrial dysfunction. These
mice exhibit a ubiquitous and progressive accumulation of
mtDNA mutations (Kujoth et al., 2005; Trifunovic et al., 2004),
which leads to a decline in mitochondrial function and an asso-
ciated premature aging phenotypewith a significantly decreased
lifespan. Mutator mice lose OXPHOS function in the central ner-
vous system but do not display overt signs of neurodegeneration
at 12 months of age, especially dopaminergic neuron loss (Dai
et al., 2013; Kujoth et al., 2005; Ross et al., 2010). This model
is highly relevant to the changes that occur during aging. Aging
is the biggest risk factor for PD, and during aging, mitochondrial
function declines and mtDNA mutations accumulate (Cottrell
et al., 2000).
Mutator mice were crossed to Parkin-KO animals to obtain
Parkin-KO, Mutator, Mutator Parkin-KO, and wild-type mice,
respectively (Figures S1A and S1C). Mice were born at the ex-
pected Mendelian ratios and appeared normal at birth, except
for a small but significant decrease in body weight of these
mice lackingParkin, as previously reported (Kimet al., 2011).Mu-
tator and Mutator Parkin-KO mice had reduced body weight at
48- to 52-weeks-of-age (Figures S1B, S1D, and S1E) and a pre-
mature aged appearance (not shown). The loss of Parkin did have
a surprising effect of partially rescuing the Mutator mouse’s
splenomegaly phenotype (Trifunovic et al., 2004) (Figure S1F).
Dopaminergic Neurons Degenerate after the Loss of
Endogenous Parkin in a Mouse Model of Mitochondrial
Dysfunction
Dopaminergic neurons were quantified from mice sacrificed at
48–52 weeks of age when mitochondria become dysfunctional
in the central nervous system of Mutator mice (Ross et al.,
2010). Wild-type, Mutator, and Parkin-KO mice displayed no
reduction in the amount of TH+ neurons relative to wild-type,
as previously reported (Dai et al., 2013; Goldberg et al., 2003).
However, Mutator Parkin-KO mice displayed a 40% reduction
in TH+ neurons in both the SN and ventral tegmental area (VTA)
regions (Figures 1A and 1B). Nissl counts ensured that the loss
of TH staining detected in Mutator Parkin-KO mice indicated
neuronal death and not a decrease or lack of TH expression (Fig-
ure 1B, right). We also analyzed the striatum in order to detect if
the axons of these dopaminergic neuronswere also affected.We
found that Mutator Parkin-KO mice at 12 months of age showed
a significant decrease in the optical density of TH+ and DAT+
fibers when compared to wild-type, Parkin-KO, and Mutator
mice (Figures 1C and 1D). We checked younger mice before
mitochondria had accumulated enough mtDNA mutations to
become dysfunctional (Ross et al., 2010). Neither TH+ neurons
nor DA striatal fibers were affected in 3-month-old Mutator
Parkin-KO mice (Figures S2A–S2D). Thus, endogenous Parkin
prevents DA neuron loss in the midbrain from the stress of mito-
chondrial damage accumulation in Mutator mice.
Another pathological sign of PD is DA depletion in the striatum,
which results from the loss of dopaminergic neurons and axonal
projections. In agreement with our other results showing a loss of
both DA neurons in the SN and striatal dopaminergic fibers
(Figures 1A–1D), DA levels were significantly reduced in Mutator
Parkin-KO mice (Figure 1E). Furthermore, 3-methoxytyramine372 Neuron 87, 371–381, July 15, 2015 ª2015 Elsevier Inc.(3-MT) but not homovanillic acid (HVA) or 3,4-dihydroxyphenyl-
acetic acid (DOPAC), which are degradation of products of DA
metabolism, was decreased in the striatal tissues of Mutator
Parkin-KO mice confirming the reduction of DA (Figure 1F).
This depletion in DA levels or metabolites was absent in
3-month-old Mutator Parkin-KO mice (Figures S2E and S2F).
The major pathological sign of PD is the presence of Lewy
bodies composed of aggregates of several proteins including
a-synuclein.Wedidnotdetecta-synucleinaggregations inourco-
horts. We used mice that overexpress mutated A53T a-synuclein
targeted specifically to dopaminergic neurons as a positive con-
trol (Figure S2I). There was no increase or presence of neuroin-
flammatorymarkers for reactive astrocytes or activatedmicroglia,
which are additional pathological indicators of PD, inMutator Par-
kin-KOmice or the other groups analyzed (Figures S2G and S2H).
We tested whether or not this degree of DA neuron loss would
cause behavioral changes. Because the loss of dopaminergic
neurons in man causes motor symptoms, we tested if nigrostria-
tal-dependent behaviors were affected in Mutator Parkin-KO
mice using the pole test. This test, which detects defects in mo-
tor coordination, has been used for other PDmousemodels, and
the behavior is dependent on nigrostriatal function (Matsuura
et al., 1997; Pickrell et al., 2011b). Mutator and Parkin-KO mice
displayed latency times descending the pole that were compara-
ble to those of wild-type mice (Figure 1G). However, Mutator
Parkin-KO mice at 48–52 weeks had significantly higher latency
times (Figure 1G). In order to test if the motor coordination de-
fects were specifically due to impairments in the nigrostriatal
pathway, we assessed Mutator Parkin-KO mice 4 weeks later
before and after L-DOPA treatment. L-DOPA is a precursor in
the DA synthesis pathway and is used to amelioratemotor symp-
toms in PD patients. L-DOPA treatment completely reverted the
motor phenotype of the Mutator Parkin-KO mice (Figure 1H;
Movie S1), indicating that the climbing impairment was specif-
ically due to the loss of dopaminergic neurons.
Neurons from Different Neuroanatomical Regions
Appear Unaffected in Mutator Parkin-KO Mice
We assessed if other neuronal populations were affected in
Mutator Parkin-KO mice. The gross brain weight and appear-
ance of Mutator Parkin-KO mice was identical to that of wild-
type mice (Figure S3C). The levels of NeuN protein, a pan
neuronal nuclei marker, in the hippocampus and cerebellum of
Mutator Parkin-KO mice appeared no different than the other
cohorts of mice, indicating that mass neurodegeneration was
absent (Figures S3A and S3B).
We also examined specific neuronal populations for evidence
of neurodegeneration. GABAergic neurons predominate among
neurons in the striatum. Although Mutator Parkin-KO mice dis-
played a loss of dopaminergic axonal innervation (Figures 1C
and 1D) in the striatum, there was no significant difference in
the number of NeuN+ (most likely composed of GABAergic neu-
rons) cells in Parkin-KO, Mutator, or Mutator Parkin-KO mice as
compared to wild-type controls (Figures 2A and 2B). The locus
coeruleus, which contains norepinephrine neurons, is another
brain region affected in PD patients (Chan-Palay and Asan,
1989). However, norepinephrine neurons of the locus coeruleus
were unaffected in Mutator Parkin-KO mice relative to control
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B Figure 1. Dopaminergic Neurons Degen-
erate after the Loss of Endogenous Parkin
in a Mouse Model of Mitochondrial
Dysfunction
(A) Representative images of the substantia nigra
detected in midbrain sections after staining with
anti-TH antibodies. Scale bar, 500 mm.
(B) The estimated number of TH+ neurons in the
substantia nigra and VTA and Nissl+ neurons in
the substantia nigra in 48- to 52-week-old mice.
n = 4/group.
(C) Representative images of striatum sections
stained with anti-TH (green) and anti-NeuN (red)
antibodies. Scale bar, 500 mm.
(D) The optical density of TH+ and DAT+ fibers
(representative images not shown) when stained
with either antibody in striatal sections of 48- to
52-week-old mice. n = 3 to 4 per group.
(E) Basal levels of DA in the striatum of 48- to
52-week-old mice normalized to the amount of
protein. n = 5/group.
(F) Basal level of DA degradation metabolites,
DOPAC, HVA, and 3-MT, found in the striatum of
48- to 52-week-old mice normalized to the amount
of protein. n = 5/group.
(G) Latency time in seconds recorded for 48- to
52-week-old mice performing the pole test.
n = 6–8/group.
(H) Latency time in seconds recorded for 56-week-
old Mutator Parkin-KO mice performing the
pole test. Each individual mouse was scored for
a baseline performance for comparison after
L-DOPA treatment. n = 4/group.
(A–H) *p < 0.05; **p < 0.01; ***p < 0.001; NS, not
significant. Mean ± SEM. ANOVA Tukey’s post
hoc test.mice (Figures 2C and 2D). Surprisingly, norepinephrine levels
were significantly elevated in Mutator Parkin-KO mice in the
olfactory bulb and striatum, two regions innervated by the locus
coeruleus (Figures 2E and S3D). Furthermore, mice exhibited a
significant increase in serotonin levels, coincident with DA neu-
rodegeneration, in these same tissues (Figures S3E–S3H). We
speculate that this could be a compensatory response to the
loss of dopaminergic neurons similar to the increases in seroto-
nin in the striatum previously reported in pharmacological PD
models in nonhuman primates and rodents (Boulet et al., 2008;
Zhou et al., 1991).
Phosphorylated Ubiquitin at S65 Is Increased during
Mitochondrial Dysfunction in the CNS
To corroborate the in vivo function of Parkin in Mutator mice, we
assessed PINK1 activity in the brains of Mutator and MutatorNeuron 87, 371–Parkin-KO mice. During mitochondrial
depolarization, PINK1, a serine/threo-
nine-protein kinase, is stabilized on mito-
chondria (Narendra et al., 2010; Pickrell
and Youle, 2015). PINK1 phosphorylates
both ubiquitin (Ub) and Parkin at serine
65 leading to Parkin’s activation and
retention on damaged mitochondria(Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al.,
2014; Ordureau et al., 2014; Wauer et al., 2015). This cascade
of events triggers translocation of Parkin specifically to damaged
mitochondria causing ubiquitylation of protein targets on the
outer mitochondrial membrane, ultimately inducing mitophagy
(Pickrell and Youle, 2015).
We used a sensitive quantitativemass spectrometry approach
to detect phosphorylated ubiquitin at S65 in vivo (Ordureau et al.,
2015a). Cortical brain tissue of Mutator mice contains 3.1 times
greater levels of phospho-S65-Ub than wild-type cortical tissue.
(Figures 3A and 3B). Interestingly, the levels of phospho-S65-Ub
in liver tissue did not differ between wild-type or Mutator mice,
possibly reflecting differences in the level of expression of
PINK1 and/or Parkin (Figures 3C and 3D). Both the liver and brain
of Mutator mice accumulate dysfunctional mitochondria (Edgar
et al., 2009), whereas the phosphorylation of Ub in response to381, July 15, 2015 ª2015 Elsevier Inc. 373
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Figure 2. Neurons from Different Neuroana-
tomical Regions Appear Unaffected in
Mutator Parkin-KO Mice
(A) Representative images of the striatum stained
with anti-NeuN antibodies. Scale bar, 20 mM.
(B) The number of NeuN-positive neurons detected
in the striatum frommice 48- to 52-week-old. n = 3
to 4/group. NS, not significant. Mean ± SEM.
ANOVA Tukey’s post hoc test.
(C) Representative images of the locus coeruleus
detected in hindbrain sections using anti-TH anti-
bodies. Scale bars, 50 mM.
(D) The number of TH+ neurons counted in the
locus coeruleus of 48- to 52-week-old mice. n = 4
to 5/group. NS, not significant. Mean ± SEM.
(E) Basal levels of norepinephrine in the olfactory
bulb and striatum of 48- to 52-week-oldmice. n = 5
to 6/group.
(A–E) *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001; NS, not significant. Mean ± SEM. ANOVA
Tukey’s post hoc test.mitochondrial dysfunction appears to be tissue specific. Addi-
tionally, we did not observe a difference between mice with
and without Parkin (Figures 3A and 3B), consistent with Parkin
functioning downstream of PINK1. Taken together, these data
suggest that the PINK1-Parkin pathway is more active in the
brains of mice that accumulate dysfunctional mitochondria.
Parkin Does Not Purify the Number of Somatic mtDNA
Point Mutations but Affects Their Pathogenicity
As mtDNA depletion occurs in the brain of Mutator mice (Wil-
liams et al., 2010), we quantified mtDNA copy number and found
a significant depletion in both Mutator and Mutator Parkin-KO
mice as compared to controls, but no significant difference be-
tween the two groups (Figure 4A). The excessive cell loss in
the Mutator Parkin-KO mice may stem from insufficient auto-
phagy of mitochondria that accumulate deleterious mtDNA mu-
tations. To assess if Mutator Parkin-KO mice accumulate more
mtDNA mutations than Mutator mice, we measured the mtDNA
mutation rate in the striatum by Sanger sequencing a portion374 Neuron 87, 371–381, July 15, 2015 ª2015 Elsevier Inc.of the mtCYTB gene. We found no differ-
ence in the number of mutations gener-
ated between Mutator and Mutator
Parkin-KO mice (Figure 4B). However,
PCR error may mask a difference be-
tween the mutation rates using traditional
sequencing methods.
To further assess the ability of Parkin
to selectively remove mitochondria
harboring deleterious mutated genomes,
we performed Duplex Sequencing to in-
crease the sensitivity and coverage and
decrease PCR error in sequencing for so-
matic mtDNA mutations (Kennedy et al.,
2013; Schmitt et al., 2012). We found a
significant increase in the mutational
frequency in Mutator and Mutator Par-
kin-KO mice relative to wild-type andParkin-KO mice; however, again there was no difference result-
ing from the absence of Parkin (Figure 4C). As expected, most
of these point mutations generated in Mutator and Mutator
Parkin-KO mice were transitions due to the misincorporation of
nucleotides during replication due to the defective polymerase
g (Figure 4H).
Although somatic nucleotide base substitutions were not
increased in Mutator Parkin-KO mice, it was possible that the
types of mutations that accumulate in mice that lacked Parkin
were more pathogenic. MutPred software was used to analyze
and score the pathogenicity of mutations detected (see Supple-
mental Experimental Procedures). We observed a slight but
significant difference in the median MutPred score between
the Mutator and Mutator Parkin-KO group and for two additional
genes, ND1 and CYTB, encoding subunits for complexes I and
III, respectively (Figures 4D–4F), but not detectably different in
the other six individual mtDNA-encoded complex I proteins (Fig-
ure S4). Interestingly, endogenous Parkin appears to decrease
the MutPred scores in Mutator mice more than in wild-type
AC D
B Figure 3. Phosphorylated Ubiquitin at S65 Is
Increased during Mitochondrial Dysfunction
in the CNS
(A) UB-AQUA proteomics of total UB, individual
UB chain linkages, and phospho-S65 UB in
whole-cell cortical lysates. Ubiquitin chain linkage
key: blue, M1 linear chains; lime, K6 linkages;
gold, K11 chain linkages; red, K27 chain linkages;
pink, K29 chain linkages (not quantifiable);
violet, K33 chain linkages; navy, K48 chain link-
ages; aqua, K63 chain linkages; green, p-S65 UB.
n = 5/group.
(B) Percentage of phospho-S65 UB normalized
to the total percentage of UB in cortical samples.
n = 5/group.
(C) UB-AQUA proteomics of total UB, individual
UB chain linkages, and phospho-S65 UB in
whole-cell liver lysates. Ubiquitin chain linkage
key: blue, M1 linear chains; lime, K6 linkages;
gold, K11 chain linkages; red, K27 chain linkages;
pink, K29 chain linkages (not quantifiable);
violet, K33 chain linkages; navy, K48 chain link-
ages; aqua, K63 chain linkages; green, p-S65 UB.
n = 5/group.
(D) Percentage of phospho-S65 UB normalized
to the total percentage of UB in liver samples.
n = 5/group.
(A–D) **p < 0.01; ***p < 0.001; NS, not significant.
Mean ± SEM. ANOVA Tukey’s post hoc test.mice, perhaps because the PINK1-Parkin pathway is activated
by mitochondrial stress. The number of point mutations, espe-
cially those in protein-coding genes, dictates the phenotype in
the Mutator mouse (Edgar et al., 2009) and the loss of Parkin
expression increased the predicted pathogenicity of the muta-
tions present. There is no significant difference in the percentage
of synonymous and non-synonymous point mutations between
groups (Figure 4G). Collectively, these data indicate that Parkin
does not select against the quantity of mtDNA mutations but
does affect the types of mutations present.
Mitochondrial Dysfunction Is Exacerbated after the Loss
of Parkin
We measured the enzymatic activity of the complexes encoded
by mtDNA. A significant defect in the enzymatic activity of com-
plexes I and III was detected in Mutator Parkin-KO mice (Fig-
ures 5A and 5B). Complex I was slightly perturbed in Mutator
mice, and complex IV activity was decreased in the striatum
of both Mutator and Mutator Parkin-KO mice (Figures 5A and
5C). To ensure that this observation was not due to reduced
mitochondrial mass, we measured the activity of citrate syn-
thase. Citrate synthase is often used as a surrogate for mito-
chondrial mass because it is the rate-limiting step in the
tricarboxylic acid cycle (TCA) cycle, which means its activity
is not dependent on mitochondrial-encoded proteins. We
observed no differences in citrate synthase activity between
groups, indicating that alterations in mitochondrial mass do
not explain the reduced complexes I and III activities (Figure 5D).Importantly, these changes in complexes I and III were not de-
tected in young Mutator Parkin-KO mice (Figures 5G and 5H). In
the Mutator Parkin-KO mice, the enzyme defects in complexes I
and III correlate with the two mitochondrial-encoded genes with
the worst MutPred scores relative to wild-type mice (Figures 4E
and 4F). Thus, Mutator Parkin-KO mice not only display specific
degeneration of the DA neurons but also biochemically mimic
PD in humans (Bender et al., 2006; Schapira et al., 1989,
1990a).
To further understand how mitochondrial OXPHOS activity
is affected by the loss of Parkin, we performed analysis on
the steady-state levels of proteins encoding OXPHOS com-
plexes and their assembly. Performing blue native-PAGE gel
analysis, we found that the complex I assembly is perturbed
in Mutator and Mutator Parkin-KO striatal mitochondria (Fig-
ures 5E and 5F); however, complexes II–V were unaffected
(Figures 5E–5F, Figure S5A). We ran western blots of SDS
gels to assess the steady-state levels of proteins that encode
different complex subunits. COXI, a mtDNA-encoded protein,
was slightly decreased in mice harboring the Mutator back-
ground (Figure S5B), but we saw no substantial difference in
the four mitochondrial subunits tested between Mutator and
Mutator Parkin-KO mice (Figure S5B). Taken together, our
data are consistent with the idea that the loss of Parkin in the
Mutator background results in the persistence of some
pathogenic mutations that would otherwise be removed,
consistent with a more severe defect in the activity of com-
plexes I and III.Neuron 87, 371–381, July 15, 2015 ª2015 Elsevier Inc. 375
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ber of Somatic mtDNA Point Mutations but
Affects Their Pathogenicity
(A) Real-time PCR detecting mtDNA copy number
using COX1 probes in the striatum of 48- to 52-
week-old mice. The nuclear gene GAPDH was
probed to normalize variance between samples.
n = 5/group.
(B) Sanger sequencing estimating the point muta-
tion rate inferred by analyzing the CYTB gene from
48- to 52-week-old striatal samples. n = 4/group.
(C) Duplex sequencing detecting the point muta-
tion rate of somatic mutations accumulating in 48-
to 52-week-old striatal samples. n = 4/group.
(D) Box plot of MutPred prediction scores from
mutations detected by Duplex sequencing in
striatal samples from mice 48–52 weeks of age.
n = 4/group. Number of variants analyzed per ge-
notype: wild-type = 335, Parkin-KO = 448, Muta-
tor = 918, and Mutator Parkin KO = 925.
(E) Box plot of MutPred prediction scores from
mutations detected byDuplex sequencing found in
CYTB in striatal samples frommice 48–52weeks of
age. n = 4/group. Number of variants analyzed per
genotype: wild-type = 43, Parkin-KO = 69, Muta-
tor = 145, and Mutator Parkin-KO = 163.
(F) Box plot of MutPred prediction scores from
mutations detected byDuplex sequencing found in
ND1 in striatal samples from mice 48–52 weeks of
age. n = 4/group. Number of variants analyzed per
genotype: wild-type = 51, Parkin-KO = 40, Muta-
tor = 89, and Mutator Parkin-KO = 90.
(G) Percentage of synonymous and non-synony-
mousmutations detected by Duplex sequencing in
48- to 52-week-old striatal samples. n = 4/group.
(H) Mutational frequency of the types of transitions
and transversions in the striatum of 48- to 52-
week-old mice. n = 4–6/group.
(A–H) *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001; NS, not significant. Mean ± SEM. ANOVA
Tukey’s post hoc test.DISCUSSION
Using themouse as amodel system, our work demonstrates that
endogenous Parkin expression protects dopaminergic neurons
from mitochondrial dysfunction. Although Parkin expression
does not significantly shift heteroplasmic point mutation levels
in the brain, it does affect the pathogenicity of these mutations.
Sterky et al. (2011) crossed a different mouse model of mito-
chondrial dysfunction with the Parkin-KO mouse and reported
no exacerbation of the phenotypes. In these mitochondrial tran-
scription factor A (TFAM)-KO/Parkin-KO mice, where TFAM is
necessary for mtDNA replication and transcription, there
was no worsening of dopaminergic neurodegeneration in the
absence of Parkin (Sterky et al., 2011). Parkin mediation of qual-
ity control at either themtDNA level or downstream at the protein
level would not be anticipated to rescue mitochondria that
cannot replicate their DNA.376 Neuron 87, 371–381, July 15, 2015 ª2015 Elsevier Inc.The Mutator Parkin-KO displays many phenotypes and
biochemical signs reminiscent of human PD. Specifically, we
found DA neuron loss, depletion of DA in the striatum, and
L-DOPA reversible motor disturbances in aged Mutator
Parkin-KO mice. However, we did not detect a-synuclein aggre-
gation or the presence of neuroinflammatory markers in
the surviving DA neurons, which are classical pathological
indicators of PD. Although neuroinflammatory processes are
observed in several neurodegenerative disorders such as
Alzheimer’s disease (AD) and Huntington’s disease (HD), the
pathologic role of inflammatory processes contributing to dopa-
minergic neuron loss in PD is not clear (Hirsch and Hunot, 2009).
It is important to note that it is still unclear if PARK2 PD patients
have Lewy body pathology (Houlden and Singleton, 2012).
Interestingly, a recent paper reports that mutant a-synuclein
overexpression induces mitophagy and that loss of Parkin exac-
erbates this phenotype (Chen et al., 2015), suggesting that
A B C D
E
G H
F
Figure 5. Mitochondrial Dysfunction Is
Exacerbated after the Loss of Parkin
(A) Complex I enzymatic activity assays measuring
striatal homogenates of 48- to 52-week-old mice.
n = 4 to 5/group.
(B) Complex III enzymatic activity assays mea-
suring striatal homogenates of 48- to 52-week-old
mice. n = 4 to 5/group.
(C) Complex IV enzymatic activity assays mea-
suring striatal homogenates of 48- to 52-week-old
mice. n = 4 to 5/group.
(D) Citrate synthase activity assays measuring
striatal homogenates of 48- to 52-week-old mice.
n = 4 to 5/group.
(E) Representative BN-PAGE gel probing for the
assembly and stabilization of complex I and III from
mitochondria isolated from the striata of 48- to
52-week-old mice.
(F) Quantification of the optical density of BN-
PAGE detected complexes I and III detected by
western blotting and normalized to GRP75 on a
SDS-PAGE gel. n = 5/group.
(G) Complex I enzymatic activity assays measuring
striatal homogenates of 12-week-old mice. n = 4 to
5/group.
(H) Complex III enzymatic activity assays mea-
suring striatal homogenates of 12-week-old mice.
n = 4 to 5/group.
(A–D and F–H) *p < 0.05; **p < 0.01; ***p < 0.001;
NS, not significant. Mean ± SEM. ANOVA Tukey’s
post hoc test.synuclein pathology may intersect the PINK1/Parkin pathway
related to mitophagy.
We also provide in vivo biochemical evidence that the PINK1-
Parkin pathway is active in the brain. It has been difficult to
assess this pathway previously due to inadequate antibodies
and the unlikelihood that neurons would physiologically undergo
the synchronized type of mitophagy induction that can be exper-
imentally induced in cultured cell lines that facilitates the detec-
tion of Parkin and LC3 accumulation on mitochondria. Mass
spectrometry yields the sensitivity to detect ubiquitin phosphor-
ylated specifically at serine 65, the product of the PINK1 kinase,
offering a biomarker of PINK1 activity. In brains of Mutator mice
with mitochondrial dysfunction, the level of phospho-S65 Ub
rises substantially. We did not find an increase in phospho-
S65 Ub in Mutator mouse liver above levels detected in wild-
type mice. This tissue specificity may shed light on why PINK1
and Parkin monogenic patients develop Parkinsonism. TheseNeuron 87, 371–data also support the notion that Parkin
is protecting the Mutator mouse through
mitophagy, where PINK1 is well estab-
lished to activate Parkin activity, than
through neuroprotective (Mu¨ller-Rischart
et al., 2013) or transcriptional activation
(Shin et al., 2011), where PINK1 has not
been shown to be involved.
Why are dopaminergic neurons specif-
ically affected? Multiple lines of evidence
support that DA neurons are under moremitochondrial stress than other neuron types. SN DA neurons,
due to their pacemaking activity, undergomild mitochondrial un-
coupling, generating excessive reactive oxygen species, and DA
metabolism drives the generation of mtDNA mutations (Guzman
et al., 2010; Neuhaus et al., 2014). Loss-of-function mutations in
Parkin and PINK1 in Drosophila lead to the accumulation of
dysfunctional mitochondria specifically in DA neurons (Burman
et al., 2012). Mitochondrial protein turnover is reduced in Parkin
and PINK1 mutant Drosophila due to decreased mitophagy (Vin-
cow et al., 2013). This causes the specific degeneration of DA
neurons with the sparing of other neuron types (serotonergic)
in Parkin mutant Drosophila (Whitworth et al., 2005). Our data
are in agreement with this model. However, because the Par-
kin-KO mice have some degree of mitochondrial dysfunction
(Palacino et al., 2004), we cannot completely rule out the possi-
bility that the synthetic phenotype occurs because we have
heightened the degree of mitochondrial dysfunction in the381, July 15, 2015 ª2015 Elsevier Inc. 377
Mutator Parkin-KO mouse. Without mitochondrial dysfunction
synergizing with the loss of Parkin, dopaminergic neuron health
is not at risk in the mouse, which is in contrast to man and
Drosophila (Palacino et al., 2004; Perez and Palmiter, 2005;
Von Coelln et al., 2004). Our results finally provide an explanation
for these puzzling findings and strongly suggest that mitochon-
drial dysfunction in aged wild-type mice does not reach high
enough levels for the loss of Parkin to have a detrimental effect.
MtDNA in the striatum shown here and in liver (Trifunovic et al.,
2004) showed no shift toward synonymous relative to non-syn-
onymous point mutations. Furthermore, inherited mtDNA muta-
tions are also unaffected by Parkin (Ma et al., 2014). How can
Parkin select against the types of mutations present without
also affecting the mutation frequency? We may not be able to
detect the subtle differences in mutational frequencies between
the Parkin-KO and Parkin+/+ backgrounds, if only a minority of
sites result in the type of dysfunction that is recognized by
PINK1/Parkin. Overexpression of Parkin reverted heteroplasmy
in COXI cybrid cells harboring high levels of a deleterious mutant
mtDNA, but was not effective in CYTB, mttRNALeu, andmtATP6
cybrid lines (Gilkerson et al., 2012; Suen et al., 2010). These data
may reveal that Parkin affects certain mutations, as we observed
that Parkin slightly decreased the pathogenicity of mtDNA pro-
tein-encoding genes overall and specifically for some complex
I and III genes (Figures 4D–4F).
Potentially counteracting Parkin purification ofmitochondria at
the DNA level is a recent finding that autophagy and mitochon-
drial clearance are inhibited in reticulocytes in Mutator mice,
and decreased autophagy in Mutator mouse embryonic fibro-
blasts is associated with increased mTOR activity (Li-Harms
et al., 2015). Wholesale mitophagy may be inhibited in Mutator
mice whereas Parkin-mediated piecemeal or selective auto-
phagy of mitochondrial debris continues to compensate for
mtDNA mutations and rescue mitochondrial function and dopa-
minergic neuron survival. Evidence by several groups suggests
that Parkin removes damaged subcomponents of mitochondria
or defective respiratory chain components from mitochondria in
human cancer cell lines, neuronal generated iPSCs, and
Drosophila (Ha¨ma¨la¨inen et al., 2013; McLelland et al., 2014; Vin-
cow et al., 2013; Yang and Yang, 2013).
Our findings suggest how Parkin-mediated quality control and
mitochondrial dysfunction contribute to pathogenesis of PD. We
find that Parkin protects dopaminergic neurons with high levels
of mtDNA mutations. We speculate that the accumulation of
mtDNA mutations in DA neurons during aging, a decline in mito-
chondrial function, and/or the loss of Parkin expression could
also be contributing factors for sporadic PD patients.EXPERIMENTAL PROCEDURES
Animals
The generation of Mutator mice was previously described (obtained from
Jackson Laboratories: B6.129S7 (Cg)-Polgtm1Tprol/J) (Kujoth et al., 2005).
Mutator mice were crossed with Parkin-KOmice (obtained from Jackson Lab-
oratories: B6.129S4-Park2tm1Shn/J) in which most of exon 3was replaced in-
frame by the coding sequence of EGFP. Exon 3 skipping causes a missense
mutation and premature termination at a stop codon in exon 5 following 49
additional out-of-frame amino acid residues (Goldberg et al., 2003). Other
mouse strain descriptions are included in the Supplemental Experimental Pro-378 Neuron 87, 371–381, July 15, 2015 ª2015 Elsevier Inc.cedures. The nuclear background of all the mouse models described here
were C57BL/6J (backcrossed at least ten generations).
Immunohistochemistry
Anesthetized mice were perfused with ice-cold 13 PBS and subsequently
sacrificed by cervical dislocation. Brains were isolated, and the regions of
interest were dissected using aMouse Brain Slicer Matrix (for midbrain, the re-
gion between 1 mm and 4 mm from Bregma; for striatum, the region
between 1 mm and +3 mm from Bregma; for hindbrain, the region between
5 mm and 6 mm from Bregma). Brain segments were submerged in 4%
paraformaldehyde at 4C overnight and cryoprotected in a 30% sucrose solu-
tion. Brains were fixed in OCT (TissueTek) and frozen by submersion into
2-methylbutane cooled in liquid nitrogen. For fluorescent immunohistochem-
istry images, 20 mm frozen sections were used. Slides were permeabilized
with 0.4% Triton x-100, blocked with 5% BSA for 1 hr at room temperature
(RT) and incubated with the following primary antibodies: anti-tyrosine hydrox-
ylase (Sigma) at 1:500, anti-DA transporter (Sigma) at 1:500, anti-NeuN (Cell
Signaling), a-synuclein at 1:250 (BioLegend), and anti-Iba-1 1:1,000 (Wako
Chemicals) ON at 4C. Alexa 488- or 594-conjugated secondary antibodies
(Invitrogen) were used for 1 hr at RT in the dark. Slides were then mounted
with fluorescent mounting media with DAPI (Vector Laboratories). Images
were captured with a LSM510 confocal microscope (Zeiss).
Stereological Neuron Counting
Forebrain, midbrain, and hindbrain were isolated as described above. To
count dopaminergic neurons, sections were cut starting from Bregma
1 mm; the first 30 slides were discarded (35 mm sections were used). Dopa-
minergic neurons were counted in every 5th section, with 10–12 total sections
counted per individual animal. Norepinephrine neurons were counted in every
4th section, with three sections counted per individual animal starting from
Bregma 5.25 mm. NeuN-positive neurons were counted in every 200 mM
section striatal sections starting at +1.45 mm (Slow et al., 2003). Stereological
counting details are in Supplemental Experimental Procedures. Slides were
permeabilized with 0.4% Triton X-100, blocked for 1 hr at RT with normal
goat serum (KPL), and incubated with anti-tyrosine hydroxylase- (Immunostar)
or anti-NeuN-positive antibodies (Cell Signaling) at 1:500. Secondary conju-
gated HRP antibodies (KPL) were used for one hour at RT. Experimenter
was blinded to genotype of each sample identified by ear tag number. Slides
were subsequently incubated with streptavidin-peroxidase (KPL) for 30 min,
visualized with 0.05%3,30-diaminobenzidine (DAB) for 7min, and/or costained
with Cresyl Violet solution (IHC World) and mounted with glycerol. Represen-
tative images were captured with an Axiovert 200 (Zeiss).
OXPHOS Complex Enzyme Activities
Complex I, IV, and citrate synthase activity were measured as previously
described (Barrientos et al., 2009). Complex III was measured according to
the manufacturer’s instructions (Cayman Chemicals). Absorbance was
measured with a SpectraMax M2 plate reader (Molecular Devices). Homoge-
nates were prepared from isolated striatum homogenized with a hand-held
rotor (VWR) in PBS-containing protease inhibitor cocktail (Roche). Activities
were normalized by the amount of protein measured by the Bradford protein
assay (BioRad).
Ubiquitin Capture and Proteomics
Ubiquitin and ubiquitylated proteins from cortex extracts (400 mg) or liver ex-
tracts (400 mg) were purified using Halo-4xUBAUBQLN1 as described (Ordureau
et al., 2014). Briefly, whole-cell extracts were incubated at 4C for 6 hr with
25 ml of Halo-4xUBAUBQLN1 beads (pack volume) in a final volume adjusted
to of 1 ml with lysis buffer (50 mM Tris/HCl [pH 7.5], 1 mM EDTA, 1 mM
EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium 2-glycerol
1-phosphate, 1 mM sodium orthovanadate, 0.27M sucrose, 1% (v/v) NP-40,
1 mg/ml leupeptin/aprotinin, 0.5 mM 4[2-aminoethyl] benzenesulfonyl fluoride
[AEBSF], 50 mM choloracetamide, and phosphatase inhibitor cocktail
[Roche]). Following four washes with lysis buffer containing 0.5 M NaCl and
five wash in 10 mM Tris (pH 8.0), proteins were released from Halo-4xU-
BAUBQLN1 beads using 6 M guanidine HCL. Samples were subjected to
TCA precipitation and digested overnight at 37C with Lys-C and trypsin
(in 100 mM TEAB, 0.1% Rapigest, 10% ACN). Digests were acidified with
equal volume of 5% formic acid (FA) to a pH 2 for 30 min, dry down, resus-
pended in 5% FA, and subjected the UB-AQUA proteomics workflow as
described below.
UB-AQUA/PRM Proteomics
UB-AQUA/PRM was performed largely as described previously but with
several modifications (Ordureau et al., 2015b; Phu et al., 2011). A collection
of heavy-labeled reference peptides each containing a single 13C/15N-
labeled amino acid was produced at Cell Signaling Technologies and quanti-
fied by amino acid analysis. The 19 UB-AQUA reference peptides used for
quantitation were previously listed in Ordureau et al. (2014). UB-AQUA pep-
tides from working stocks (in 5% FA) were diluted into the digested sample
(in 5% FA) to be analyzed to an optimal final concentration predetermined
for individual peptide such that each peptide’s intensity would be ranging be-
tween 106 and 108. Samplesmixed to AQUA peptides were oxidizedwith 0.1%
hydrogen peroxide for 30 min, subjected to C18 StageTip desalting, and re-
suspended in 5% FA. Experiments were performed with five independent bio-
logical samples and analyzed sequentially by mass spectrometry. Our MS
data were collected using a Q Exactive mass spectrometer (Thermo Fisher
Scientific) coupledwith a Famos Autosampler (LCPackings) and an Accela600
LC pump (Thermo Fisher Scientific). Peptides were separated on a 100-mm i.d.
microcapillary column packed with 0.5 cm of Magic C4 resin (5 mm, 100 A˚;
Michrom Bioresources) followed by 20 cm of Accucore C18 resin (2.6 mm,
150 A˚; Thermo Fisher Scientific). Peptides were separated using a 60 min
gradient of 3%–25% acetonitrile in 0.125% FA with a flow rate of
300 nl,min1. The scan sequence began with an Orbitrap full MS1 spectrum
with the following parameters: resolution of 70,000, scan range of 200–1,000
Thomson (Th), AGC target of 1 3 106, maximum injection time of 250 ms,
and profile spectrum data type. This scan was followed by 12 targeted MS2
scans selected from a scheduled inclusion list with a 5 min retention time win-
dow. Each targeted MS2 scan consisted of high-energy collision dissociation
(HCD) with the following parameters: resolution of 35,000, AGC of 1 3 106,
maximum injection time of 200 ms, isolation window of 1 Th, normalized colli-
sion energy (NCE) of 27, and profile spectrum data type. Raw files were
searched and precursor and fragment ions quantified using Skyline version
3.1 (MacLean et al., 2010). Data generated from Skyline was exported into a
Microsoft Excel spread sheet and GraphPad Prism for further analysis as pre-
viously described (Ordureau et al., 2014). Total UB amount was determined as
the average of the total UB calculated for each individual locus (Phu et al.,
2011). Samples were normalized to total amount of UB (1,000 fmol).
Duplex Sequencing
Duplex Sequencing was performed as previously described (Kennedy et al.,
2014; Schmitt et al., 2012) with several modifications. Briefly, 500 ng of total
DNA was sonicated in 60 ml of nuclease-free ddH2O and subjected to end-
repair and 30-dA-tailing using the NEBNext Ultra End-Repair/dA-Tailing
Module (New England Biolabs) according to the vendor’s instructions. A
20:1 molar excess of Duplex Sequencing adapters was ligated to the sample
DNA using the NEBNext Ultra Ligation Module (New England Biolabs). After
ligation, bead cleaning and PCR amplification were performed as previously
described (Kennedy et al., 2014), and the mtDNA was isolated using the
Agilent SureSelectXT Target Enrichment System (Agilent) with probes specific
for the mouse mitochondrial genome following the manufacturer’s instruc-
tions. The captured DNA samples were then sequenced on an Illumina
HiSeq2500 using 101 bp paired-end sequencing. After sequencing, the reads
were aligned against the mouse genome (GRCm38) and processed using a
custom software workflow described previously (Kennedy et al., 2014). Reads
not uniquelymapping to themitochondrial genomewere excluded from further
analysis. After processing, we called de novo somatic mutations by using a
clonality cutoff that excluded variants occurring at a frequency of >1% and
positions with <1003 depth. Mutations were scored only once at each position
of the genome.
BN PAGE Gels
Mitochondrial isolation from striatal tissue has been previously described
(Pickrell et al., 2011a). In brief, anesthetized animals were killed immediatelyand regionally dissected brain regions were homogenized in a Dounce glass
homogenizer (eight to ten strokes) in SEE buffer (250 mM sucrose, 10 mM
HEPES [pH 7.4], 0.5 mM EDTA [pH 7.4], and 0.5 mM EGTA) with the addition
of 50 mg/ml BSA and protease inhibitor mixture (Roche) before use. The ho-
mogenate was spun on a Sorvall Superspeed RC2-B centrifuge at 4C at
2,000 3 g for 5 min. The supernatant was removed and spun at 12,000 3 g
for 8 min. The pellet was resuspended in SEE buffer and respun. A final spin
of the resuspended pellet was performed in 250 mM sucrose. The final pellet
was resuspended in mitochondria incubation buffer (pH 7.2) (130 mM KCl,
2 mM KH2PO4, 2 mM MgCl2, 10 mM HEPES, and 1 mM EDTA). Proteins in
the final suspension were measured using the Bradford methodology with a
BSA standard curve using Bio-Rad Protein Assay dye (Bio-Rad).
To examine the integrity of the individual mitochondrial respiratory com-
plexes, blue native electrophoresis was performed with 60 mg of isolated mito-
chondria from striatum. Mitochondria were treated with 1% lauryl maltoside
(Sigma) for 20 min on ice. The solubilized material was cleared by centrifuga-
tion for 20 min at 14,000 3 g. One third of the cleared material was loaded on
SDS-PAGE to assess the total protein levels, while the rest was loaded on a
4%–16% acrylamide gradient BN-PAGE gel (Invitrogen). Both gels were trans-
ferred to PVDF membranes and incubated with antibodies against the individ-
ual respiratory complexes.
Membranes were blocked in 5%milk for 1 hr at RT. Primary antibodies used
were anti-NDUFA9 1:500, anti-SDHB 1:1,000, anti-UQCRC2 1:4,000, anti-
MTCOXI 1:1,000, and anti-ATP5A 1:5,000 (all from Abcam). For total protein
analysis by SDS-PAGE, the antibodies against Grp75 (1:1,000) were used. Pri-
mary antibodies were incubated overnight at 4C. Secondary antibodies were
used at 1:5,000 concentrations 1 hr RT. Blots were exposed with ECL Prime
(GE Healthcare) detected with the ChemiDoc system (BioRad). Semiquantita-
tive optical densitymeasurements of band intensity were takenwith Image Lab
software (BioRad).
Approvals
All mice procedures were performed according to a protocol approved by the
National Institutes of Health NINDS Institutional Animal Care and Use Commit-
tee. Mice were housed in a virus-antigen-free facility at the NIH Division of
Veterinary Resources in a 12 hr light/dark cycle at RT and fed ad libitum with
a standard rodent diet.
Statistics
A one-way ANOVA was performed for multiple comparisons with Tukey post
hoc analysis; p % 0.05 determined significance. The number of observa-
tions/animals used in each experimental series was included in the figure
legends.
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